Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Regeneron Pharmaceuticals, Inc. (REGN) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Regeneron Pharmaceuticals, Inc. (REGN) lobbying for?
Summary of lobbying data: Regeneron Pharmaceuticals, Inc. hired five lobbying firms to lobby on general issues such as Taxation/Internal Revenue Code, Health Issues, Medicare/Medicaid, Copyright/Patent/Trademark, and Budget/Appropriations. They also lobbied on specific issues such as coverage, Medicare, and pricing; pandemic response measures, patent issues relating to biopharmaceutical manufacturers; intellectual property rights, access, innovation, including manufacturing and budget appropriation issues, TRIPS waivers, payment for ophthalmic drugs, and implementation of the Inflation Reduction Act. Regeneron Pharmaceuticals, Inc. lobbied on these issues with the White House Office, House of Representatives, Food & Drug Administration (FDA), Department of Health & Human Services (HHS), Senate, and Department of Commerce (DOC).
One could infer that Regeneron Pharmaceuticals, Inc. is lobbying on these issues in order to promote their interests and protect their intellectual property rights. The company also seems to be actively seeking to influence government policies and budget appropriations related to biopharmaceuticals and pandemic preparedness/response. Additionally, they seem to be invested in advocating for increased access and payment for their products, as well as pushing for favorable tax policies and incentives.
